12
12V.F Veracyte Inc
- Market cap
- EUR 1.73B
- P/E
- 16.2x
- P/B
- 1.43x
- ROE
- 8.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 12V.F undervalued?
Graham number12V.F trades 1.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Veracyte Inc fundamental analysis
No fundamental analysis for Veracyte Inc yet.
Veracyte Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system servic…
Full company profileVeracyte Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Veracyte Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 65.1M | 72.0M | 92.0M | 120M | 117M | 220M | 297M | 361M | 446M | 517M | 588M |
| Gross Profit | 39.6M | 43.8M | 58.9M | 83.8M | 76.0M | 145M | 195M | 230M | 298M | 363M | 422M |
| Operating Income | -28.8M | -26.5M | -22.2M | -15.1M | -35.4M | -81.9M | -41.1M | -17.4M | 19.5M | 78.3M | 82.9M |
| EBITDA | - | -23.8M | -17.1M | -7.81M | -26.7M | -62.3M | -15.2M | -49.4M | 49.2M | 89.6M | 125M |
| Net Income | -31.4M | -31.0M | -23.0M | -12.6M | -34.9M | -75.6M | -36.6M | -74.4M | 24.1M | 66.4M | 114M |
| EPS | - | -0.91 | -0.56 | -0.25 | -0.60 | -1.06 | -0.51 | -1.02 | 0.31 | 0.84 | 1.42 |
| Balance Sheet | |||||||||||
| Total Assets | 101M | 78.7M | 121M | 275M | 457M | 1.19B | 1.16B | 1.11B | 1.30B | 1.41B | 1.57B |
| Total Liabilities | 41.5M | 41.4M | 40.9M | 35.8M | 35.9M | 91.3M | 81.2M | 70.8M | 124M | 96.4M | 140M |
| Shareholders' Equity | 59.6M | 37.2M | 79.8M | 239M | 421M | 1.10B | 1.08B | 1.04B | 1.18B | 1.31B | 1.43B |
| Cash & Short-term Investments | 59.2M | 33.9M | 78.0M | 159M | 349M | 173M | 154M | 216M | 239M | 363M | 200M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -28.0M | -23.9M | -13.5M | -3.23M | -9.71M | -31.6M | 7.54M | 38.4M | 75.1M | 136M | 162M |
| Capital Expenditure | 4.21M | 1.76M | 1.87M | 2.76M | 2.84M | 5.38M | 8.55M | 9.34M | 11.3M | 9.68M | 10.9M |
| Free Cash Flow | - | -25.7M | -15.4M | -5.99M | -12.5M | -37.0M | -1.01M | 29.1M | 63.8M | 127M | 151M |
| Ratios | |||||||||||
| ROE | -52.6% | -83.3% | -28.8% | -5.3% | -8.3% | -6.9% | -3.4% | -7.1% | 2.1% | 5.1% | 8.0% |
| ROA | -31.0% | -39.4% | -19.1% | -4.6% | -7.6% | -6.4% | -3.2% | -6.7% | 1.9% | 4.7% | 7.3% |
| Net Profit Margin | -48.2% | -43.1% | -25.0% | -10.5% | -29.7% | -34.4% | -12.3% | -20.6% | 5.4% | 12.8% | 19.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Veracyte Inc dividends
Veracyte Inc has not paid dividends in the last 9 fiscal years.
Who owns Veracyte Inc
- Insiders 0.53%
- Institutions 99.47%
- Public & others 0.00%
- Shares outstanding 80.7M
- Free float 80.2M
Veracyte Inc company profile
- Company name
- Veracyte Inc
- Ticker
- 12V.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 755
- Fiscal year end
- December
- Address
- 6000 Shoreline Court, South San Francisco, CA, United States, 94080
- Phone
- 650 243 6300
- Website
- veracyte.com
About Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Veracyte Inc management
10- Mr. Marc A. StapleyCEO & Director · born 1970
- Ms. Rebecca ChambersExecutive VP & CFO · born 1978
- Dr. Phillip G. Febbo M.D.Chief Scientific & Medical Officer · born 1966
- Ms. Annie McGuireExecutive VP, General Counsel & Head of Market Access · born 1980
- Dr. John Leite Ph.D.Global Chief Commercial Officer · born 1972
- Dr. Keith Gligorich Ph.D.Senior Vice President of Global Operations
- Mr. Jonathan WygantVP & Chief Accounting Officer · born 1971
- Dr. Kevin Richard Haas Ph.D.Chief Development & Technology Officer · born 1985
- Mr. Steven FrenchSenior VP & Chief Information Officer
- Ms. Kelly GuraDirector of Investor Relations